2 (Type) of the Automated Export Reporting Program (AERP) record layout. This indicator code should be used in lieu of the domestic (D) or foreign (F) indicator code required in those fields on the SED Form, the AES record, and the AERP record. The FMS indicator code will serve to identify more accurately that segment of U.S. exports that represent FMS deliveries in the U.S. export statistics.

* * * * *

Dated: July 16, 1998.

Bradford R. Huther,

Deputy Director, Bureau of the Census.

[FR Doc. 98–20616 Filed 7–31–98; 8:45 am]

BILLING CODE 3510–07–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 510

Animal Drugs, Feeds, and Related Products; Change of Sponsor

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor for an approved new animal drug application (NADA) from Ohmeda Pharmaceutical Products Division, Inc., to Baxter Pharmaceutical Products, Inc.

EFFECTIVE DATE: August 3, 1998.

FOR FURTHER INFORMATION CONTACT: Thomas J. McKay, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

SUPPLEMENTARY INFORMATION: Ohmeda Pharmaceutical Products Division, Inc., Liberty Corner, NJ 07938–0804, has informed FDA that it has transferred the ownership of, and all rights and interests in, approved NADA 135–773 (isoflurane) to Baxter Pharmaceutical Products, Inc., 110 Allen Rd., P.O. Box 804, Liberty Corner, NJ 07938. The new sponsor will retain the drug labeler code for Ohmeda, Pharmaceutical Products, Inc. The agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the new sponsor name.

List of Subject in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for ''Ohmeda Pharmaceutical Products Division, Inc.,'' and by alphabetically adding an entry for ''Baxter Pharmaceutical Products, Inc., 110 Allen Rd., Liberty Corner, NJ 07938''; and in the table in paragraph (c)(2) in the entry for ''010019'' by removing the sponsor name ''Ohmeda Pharmaceutical Products Division, Inc.,'' and adding in its place ''Baxter Pharmaceutical Products, Inc., 110 Allen Rd.,''.

Dated: July 10, 1998.

Margaret Ann Miller,

Acting Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 98–20531 Filed 7–31–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 510

Animal Drugs, Feeds, and Related Products; Change of Sponsor Name

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect the change of sponsor name from Rhone-Poulenc Chemicals, Ltd., to Rhodia Limited.

EFFECTIVE DATE: August 3, 1998.

FOR FURTHER INFORMATION CONTACT: Thomas J. McKay, Center for Veterinary Medicine (HFV–102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0213.

SUPPLEMENTARY INFORMATION: Rhone-Poulenc Chemicals, Ltd., P.O. Box 46, St. Andrews Rd., Avonmouth, Bristol BS119YF, England, UK, has informed FDA of a change of sponsor name to Rhodia, Limited. Accordingly, the agency is amending 21 CFR 510.600(c)(1) and (c)(2) to reflect the change of sponsor name.

List of Subjects in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

§ 510.600 [Amended]

2. Section 510.600 *Names, addresses, and drug labeler codes of sponsors of approved applications* is amended in the table in paragraph (c)(1) by removing the entry for ''Rhone-Poulenc Chemicals, Ltd.,'' and by alphabetically adding an entry for ''Rhodia Limited''; and in the table in paragraph (c)(2) in the entry for ''059258'' by removing the sponsor name for ''Rhone-Poulenc Chemicals, Ltd.,'' and adding in its place ''Rhodia Limited''.

Dated: July 10, 1998.

Margaret Ann Miller,

Acting Director, Office of New Animal Drug EvaluationCenter for Veterinary Medicine.

[FR Doc. 98–20532 Filed 7–31–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520

Oral Dosage Form New Animal Drugs; Milbemycin Oxime Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Novartis Animal Health US, Inc. The supplemental NADA provides for use of a lower dose of milbemycin oxime in treating dogs and puppies for the prevention of heartworm disease.

EFFECTIVE DATE: AUGUST 3, 1998.